Neoleukin Therapeutics, Inc.
NASDAQ:NLTX
3.49 (USD) • At close December 18, 2023
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0 | 0.006 | 0.451 | 0 | 25 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit
| 0 | 0.006 | 0.451 | 0 | 25 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit Ratio
| 0 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 41.129 | 39.162 | 24.344 | 4.417 | 41.789 | 36.267 | 28.382 | 15.799 | 18.079 | 7.539 | 6.045 |
| General & Administrative Expenses
| 17.968 | 21.536 | 17.21 | 18.826 | 15.835 | 14.852 | 9.263 | 5.541 | 4.296 | 1.777 | 1.636 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 17.968 | 21.536 | 17.21 | 18.826 | 15.835 | 14.852 | 9.263 | 5.541 | 4.296 | 1.777 | 1.636 |
| Other Expenses
| -0.042 | 0.006 | -0.044 | -0.008 | -0.445 | -0.039 | -0.043 | -0.369 | -0.255 | 0 | 0.064 |
| Operating Expenses
| 59.097 | 60.698 | 41.554 | 23.243 | 57.624 | 51.119 | 37.645 | 21.34 | 22.376 | 9.376 | 7.681 |
| Operating Income
| -59.097 | -60.698 | -33.728 | -70.959 | -32.624 | -51.119 | -37.645 | -21.34 | -23.566 | -9.376 | -7.662 |
| Operating Income Ratio
| 0 | -10,116.333 | -74.785 | 0 | -1.305 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 1.54 | 0.006 | 0.451 | 1.517 | -0.52 | -0.058 | 0.025 | -0.421 | 0.694 | 0.658 | 0.064 |
| Income Before Tax
| -57.557 | -60.692 | -33.277 | -69.442 | -31.585 | -50.183 | -37.002 | -21.86 | -24.027 | -8.734 | -7.672 |
| Income Before Tax Ratio
| 0 | -10,115.333 | -73.785 | 0 | -1.263 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| -1.54 | -2.277 | -8.321 | -0.007 | -1.043 | -0.94 | -0.644 | 0.421 | -0 | -0.005 | 0.042 |
| Net Income
| -56.017 | -58.415 | -24.956 | -69.435 | -31.585 | -50.183 | -37.002 | -21.86 | -23.821 | -9.3 | -12.138 |
| Net Income Ratio
| 0 | -9,735.833 | -55.335 | 0 | -1.263 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -1.01 | -1.06 | -0.48 | -2.57 | -1.34 | -2.14 | -1.96 | -1.73 | -2.75 | -0.93 | -2.08 |
| EPS Diluted
| -1.01 | -1.06 | -0.48 | -2.57 | -1.34 | -2.14 | -1.96 | -1.73 | -2.75 | -0.93 | -2.08 |
| EBITDA
| -56.485 | -60.698 | -47.564 | -21.369 | -31.506 | -50.16 | -37.069 | -21.709 | -24.379 | -9.676 | -7.532 |
| EBITDA Ratio
| 0 | -10,116.333 | -105.463 | 0 | -1.26 | 0 | 0 | 0 | 0 | 0 | 0 |